Related Experiment Video
Updated: Jul 16, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview
M D Flather1, S Yusuf, L Køber
1Preventive Cardiology and Therapeutic Research Program, Hamilton Health Sciences Corporation Research Centre, McMaster University, Ontario, Canada.
Insights
Angiotensin-converting enzyme (ACE) inhibitors significantly reduce mortality and hospital readmissions in patients with heart failure or left-ventricular dysfunction. These benefits, observed early and long-term, apply across diverse patient groups.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Prospective systematic overview of individual patient data from five long-term randomized trials.
- Focus on angiotensin-converting enzyme (ACE) inhibitors for left-ventricular dysfunction or heart failure.
Purpose of the Study:
- To evaluate the efficacy of ACE inhibitors in reducing mortality and morbidity in patients with left-ventricular dysfunction or heart failure.
Main Methods:
- Meta-analysis of individual patient data from 12,763 participants across five randomized trials.
- Peto-Yusuf method used for data combination.
- Trials included patients within one week post-myocardial infarction and those with heart failure.
Main Results:
- ACE inhibitors significantly reduced mortality (23.0% vs 26.8%) and reinfarction (8.9% vs 11.0%) across all trials.
- Reduced rates of heart failure readmission (13.7% vs 18.9%) and composite events (33.8% vs 41.0%) were observed.
- Benefits were consistent regardless of age, sex, or concomitant medications, and persisted long-term.
Conclusions:
- ACE inhibitors are highly effective in improving outcomes for patients with left-ventricular dysfunction and heart failure.
- Early and sustained benefits suggest ACE inhibitors as a cornerstone therapy in cardiovascular disease management.
Background:
We undertook a prospective systematic overview based on data from individual patients from five long-term randomised trials that assessed inhibitors of angiotensin-converting enzyme (ACE) in patients with left-ventricular dysfunction or heart failure.
Methods:
Three of the trials enrolled patients within a week after acute myocardial infarction. Data were combined by use of the Peto-Yusuf method.
Findings:
Overall 12,763 patients were randomly assigned treatment or placebo and followed up for an average of 35 months. In the three post-infarction trials (n=5,966), mortality was lower with ACE inhibitors than with placebo (702/2995 [23.4%] vs 866/2971 [29.1%]; odds ratio 0.74 [95% CI 0.66-0-83]), as were the rates of readmission for heart failure (355 [11.9%] vs 460 [15.5%]; 0.73 [0.63-0.85]), reinfarction (324 [10.8%] vs 391 [13.2%]; 0.80 [0.69-0.94]), or the composite of these events (1049 [35.0%] vs 1244 [41.9%]; 0.75 [0.67-0.83]; all p
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

